RESUMEN
Carbapenem resistance due to metallo-beta-lactamases (MBLs) is a global phenomenon and an important challenge for antibiotic therapy (Boyd et al., 2020 [1]). While previous reports have demonstrated both in vitro and in vivo synergy using the combination of ceftazidime-avibactam and aztreonam against Stenotrophomonas maltophilia, an MBL-harboring organism, this treatment strategy has not been reported during pregnancy (Mojic et al., 2017 [2], [3], Mojica et al., 2016 [4], Alexander et al., 2020 [5]). We describe a 33-year-old pregnant female with polymicrobial, bilateral pyelonephritis caused by Stenotrophomonas maltophilia and other gram-negative bacteria. The organisms were eradicated with the combination of ceftazidime-avibactam and aztreonam followed by successful delivery with no observed adverse effects in either mother or child post-partum.
RESUMEN
A cat receiving chemotherapy for lymphoma was administered a four times overdose of vinblastine in error. Severe, acute life-threatening toxicities occurred. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) was suspected based on electrolyte disturbances. A favourable outcome was achieved with aggressive supportive care. Personnel involved in administering chemotherapy to small animal patients must check that the patient is receiving the correct drug, at the appropriate dose, prior to every treatment.
Asunto(s)
Antineoplásicos Fitogénicos/efectos adversos , Enfermedades de los Gatos/inducido químicamente , Errores de Medicación/veterinaria , Vinblastina/efectos adversos , Equilibrio Hidroelectrolítico/efectos de los fármacos , Animales , Antineoplásicos Fitogénicos/uso terapéutico , Enfermedades de los Gatos/tratamiento farmacológico , Gatos , Sobredosis de Droga/veterinaria , Femenino , Linfoma/tratamiento farmacológico , Linfoma/veterinaria , Vinblastina/uso terapéuticoRESUMEN
Recently society has been witnessing the rise of a new era in the prevention and treatment of the metabolic syndrome and cardiovascular disease: the Polyera. This new era started when a promising concept - the Polypill - was introduced by Wald et al. in 2003. The Polypill is a theoretical combination of six pharmacological compounds (a statin, three different antihypertensives, aspirin, and folic acid) that in combination could reduce cardiovascular disease by more than 80%. Although the Polypill could theoretically be a highly effective intervention, it is not yet available in the market and its effectiveness remains unproven. In the population at large, cheap prizes may come at prohibitive costs. With frail elderly and population prevalences of co-morbidity far higher than in drug trials, rare adverse effects may be frequent. In December 2004, a more natural, safer, and probably tastier alternative to the Polypill - the Polymeal - was introduced. Contrary to the Polypill, the Polymeal combined 6 different foods (fruits and vegetables, almonds, chocolate, wine, fish, and garlic) that taken together in a regular basis could cut cardiovascular disease risk by over 75%. Polyproducts from the polyera in true populations might hide unexpected polyinteractions. In the polyera, polytrials will need to establish benefits, harms, and costs.